Fetuin-A pretransplant serum levels, kidney allograft function and rejection episodes: A 3-year posttransplantation follow-up

Kidney and Blood Pressure Research

Volumn 34, Issue 5, 2011, Pages 328-333

  Roos, Marcel ^a,d   Heinemann, Falko M ^b   Lindemann, Monika ^b   Horn, Peter A ^b   Lutz, Jens ^a   Stock, Konrad ^a   Thürmel, Klaus ^a   Baumann, Marcus ^a   Witzke, Oliver ^c   Heemann, Uwe ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Institute for Transfusion Medicine   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fetuin A; Graft failure; Kidney transplantation; Rejection

Indexed keywords

FETUIN A;

ADULT; AGED; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80955173518     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000327848     Document Type: Article

References (28)

1. Matas AJ, Humar A, Gillingham KJ, et al: Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002; 62: 704-714. (Pubitemid 34784617)
2. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, Cosio FG: Identifying specific causes of kidney allograft loss. Am J Transpl 2009; 9: 527-535.
3. Schwarz A, Mengel M, Gwinner W, Radermacher J, Hiss M, Kreipe H, Haller H: Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341-348. (Pubitemid 40019257)
4. Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, Schwarz A: Early calcification of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Transplant 2005; 5: 1934-1941. (Pubitemid 41039868)
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383. (Pubitemid 38282293)
6. 2007 Annual Data Report. Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2008; 51:S1-S319.
7. Dziegielewska KM, Brown WM: Fetuin. Heidelberg, Springer, 1995.
8. Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ: Origin of plasma alpha2HS- glycoprotein and its accumulation in bone. Nature 1976; 262: 226-227.
9. Keeley KW, Sitarz EE: Identification and quantitation of alpha 2-HS-glycoprotein in the mineralized matrix of calcified plaques of atherosclerotic human aorta. Atherosclerosis 1985; 55: 63-69. (Pubitemid 15064939)
10. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW: Fetuin/alpha2-HS glycoprotein is a transforming growth factor- beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996; 271: 1275-1276.
11. Verma-Gandhu M, Peterson MR, Peterson TC: Effect of fetuin, a TGF beta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis. Eur J Pharmacol 2007; 572: 220-227. (Pubitemid 47429640)
12. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003; 361: 827-833. (Pubitemid 36331846)
13. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M, Nordfors L: Low fetuin- A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392. (Pubitemid 41623401)
14. Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Eyileten T, Sonmez A, Oguz Y, Oner K, Ors F, Vural A, Yenicesu M: Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007; 83: 392-397. (Pubitemid 46667841)
15. Urbanová M, Kalousová M, Zima T, Skibová J, Wohlfahrt P, Viklický O: Fetuin-A early after renal transplantation. Kidney Blood Press Res 2009; 32: 217-222.
16. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: Evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118-1129. (Pubitemid 10232592)
17. Heinemann FM, Rebmann V, Witzke O, Philipp T, Broelsch CE, Grosse-Wilde H: Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 2007; 83: 706-711. (Pubitemid 46569187)
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
19. Nankivell BJ, Chapmann BJ: Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643-654.
20. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin- A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366. (Pubitemid 38063764)
21. Moe SM, Chen NX: Inflammation and vascular calcification (review). Blood Purif 2005; 23: 64-71.
22. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE: Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 1676-1685. (Pubitemid 41418594)
23. Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C: Serum fetuin-a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008; 44: 323-327.
24. Abedini S, Holme I, März W, Weihrauch G, Fellström B, Jardine A, Cole E, Maes B, Neumayer HH, Grønhagen-Riska C, Ambühl P, Holdaas H, ALERT study group: Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246-1254.
25. Goldfarb-Rumyantzev AS, Naiman N: Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant 2010; 25: 1039-1047.
26. Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, Scher LA, Friedman SG, Tracey KJ: Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001; 15: 181-185. (Pubitemid 33599100)
27. Ciaccio M, Bivona G, Di Sciacca R, Iatrino R, Di Natale E, Li Vecchi M, Bellia C: Changes in serum fetuin-A and inflammatory markers levels in end-stage renal disease (ESRD): Effect of a single session haemodialysis. Clin Chem Lab Med 2008; 46: 212-214.
28. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68.